Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
One of the best tools to help practitioners make the best bedside clinical decisions when managing patients with acute cardiovascular diseases.
A comprehensive guidelines implementation toolkit especially for Nurses & Allied Professionals.
Dr. Ines Frederix
Dr. Michael Mcintosh
The ESC Prevention of CVD Programme Page on beta-blockers will provide the reader with information regarding the modes of action and cardiovascular effects of beta-blockers, the indications, the contraindications, and the major adverse effects of these drugs. In addition, the typical types and dosages of beta-blockers are summarized.
Types and typical dosages of the most frequently used beta-blockers .
Practical recommendations for the use of beta-blockers in daily practice 
 De Sutter J, Mendes M, Franco OH. Chapter 19 Cardioprotective drugs. In: Gielen S, De Backer G, Piepoli MF, Wood D, editors. The ESC Textbook of Preventive Cardiology. 2nd ed. United Kingdom: Oxford University Press, 2016.
 Steg G, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–2619.
 Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013; 34: 2949–3003.
 Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 2129-2200.
The ESC Prevention of Cardiovascular Disease programme is supported by AMGEN, AstraZeneca, Ferrer, and Sanofi and Regeneron in the form of educational grants.
< ACE inhibitors & ARBs
Statins & more >
Our Mission: To Reduce the Burden of Cardiovascular Disease
© 2019 European Society of Cardiology. All rights reserved